Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Shaoqing Ai | Cancer | Best Researcher Award

Published on by Cell Biologist

Mr. Shaoqing Ai | Cancer | Best Researcher Award

Xi’an Daxing Hospital | China

Dr. Shaoqing Ai’s research focuses on the clinical application and translational potential of integrated traditional Chinese and Western medicine in oncology, particularly in the management of gastrointestinal tumors, lung cancer, and gynecological malignancies. His work emphasizes optimizing multidisciplinary treatment strategies and improving patient outcomes through precision diagnosis and therapy. As an active contributor to the fields of tumor metastasis and geriatric oncology, he has participated in a research project exploring the molecular mechanisms and clinical management of tumor progression and treatment-related complications. His published studies, including one SCI-indexed paper and two Chinese core journal articles, highlight the therapeutic efficacy of combined treatment approaches in reducing radiotherapy- and chemotherapy-induced hematologic toxicities such as leukopenia and thrombocytopenia. Dr. Ai’s research also aims to refine clinical protocols for mitigating adverse effects while enhancing the overall quality of life for cancer patients. Through his involvement in professional oncology committees and collaborative studies, he continues to advance the integration of evidence-based Chinese medicine with modern oncological practices, contributing to the growing body of knowledge supporting individualized and holistic cancer care.

Profile: Orcid

Featured Publications:

Ai, S., Jun, G., Jia, W., & Jie, L. (2025, October 16). Correlation analysis between frequency of gastrointestinal bleeding episodes and abnormal coagulation indexes in digestive system tumors. Scientific Reports. https://doi.org/10.1038/s41598-025-19012-8

 

 

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Published on by Cell Biologist

Dr. Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a clinical research fellow at the Institute of Genetics and Cancer, University of Edinburgh, with over fourteen years of dedicated experience in translational and clinical cancer research. Since his early days in medical school, he has pursued a strong passion for advancing oncology through both laboratory and clinical investigations, contributing to more than 60 peer-reviewed publications that have collectively garnered over 2,300 citations, with a Google Scholar H-index of 28. His research spans biomaterials, nanomedicine, wound healing, immunoinformatics, and cancer vaccine design, with several of his papers ranking among the top 1% most-cited in their respective years of publication. Notably, his work on innovative wound dressings, cancer-testis antigen vaccines, and gold nanoclusters for radiosensitization has made significant impacts within the fields of biomaterials and cancer therapeutics. Alongside his research, he is currently advancing his academic qualifications through a Postgraduate Certificate of Academic Practice at the University of Edinburgh and Associate Principal Investigator Training with NIHR. Recognized among the top 0.5% of cancer researchers worldwide, his career reflects a consistent commitment to bridging basic science and clinical application to improve patient care.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., Amini Baghbadorani, M., & Navid, S. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., & Rafienia, M. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Karbasi, S. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Evgeny Deforzh | Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.

Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Icahn School Of Medicine At Mount Sinai | United States

Alexander Tsankov is a leading researcher in computational biology and cancer genomics, known for his contributions to single-cell and spatial transcriptomics. He holds dual bachelor’s degrees in Plan II Honors and Electrical and Computer Engineering from the University of Texas at Austin, and earned his M.S. and Ph.D. in Electrical Engineering and Computer Science from MIT. His research focuses on understanding the cellular and molecular mechanisms underlying cancer progression and tissue remodeling, with an emphasis on glioblastoma, lung adenocarcinoma, and colorectal cancer. Dr. Tsankov has published extensively in top-tier journals such as Nature, Nature Communications, Cancer Discovery, Nature Genetics, and Immunity. He has authored over 50 peer-reviewed publications, with an h-index of 36 and more than 15,000 citations according to Google Scholar. His work has earned him several prestigious honors, including the NIH NRSA postdoctoral fellowship and the NSF graduate fellowship. Dr. Tsankov frequently serves as a senior or corresponding author, highlighting his leadership in the field of computational oncology and single-cell genomics.

Profile: Google Scholar

Featured Publications:

  • “Learning the cellular origins across cancers using single-cell chromatin landscapes”

  • “Cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma”

  • “Single cell profiling of human airway identifies tuft-ionocyte progenitor cells displaying cytokine-dependent differentiation bias in vitro”

  • “Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma”

  • “Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches”

  • “Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer”

  • “NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma”

  • “Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations”

  • “Single cell view of tumor microenvironment gradients in pleural mesothelioma”

  • “Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines”

Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Published on by Cell Biologist

Dr. Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Dr. Sunila Pradeep | The Medical College of Wisconsin | United States

Dr. Sunila Pradeep, Ph.D., is an accomplished Associate Professor at the Medical College of Wisconsin, with over two decades of academic and research experience in immunology, oncology, and translational medicine. Originating from India, Dr. Pradeep began her journey in microbiology before delving deep into cancer research. Her multidisciplinary work bridges basic science with clinical relevance, particularly in ovarian and uterine cancers. Having trained in globally recognized institutions like the Weizmann Institute (Israel) and MD Anderson Cancer Center (USA), she has cultivated a robust research portfolio. Her impact in biomedical sciences is well-established. Dr. Pradeep’s ongoing work on extracellular vesicles, tumor microenvironment, and therapy resistance showcases her commitment to solving real-world clinical problems. A recipient of numerous national and international honors, she is a role model for aspiring women in science, blending scientific rigor with compassionate mentorship.

Publication Profile: 

Scopus

Education:

Dr. Sunila Pradeep’s academic path began in India, where she completed her B.Sc. and M.Sc. in Microbiology at Bharathiar University, Coimbatore, Tamil Nadu. Her passion for biomedical sciences led her to pursue a Ph.D. in Immunology at the University of Calicut, Kerala, under the mentorship of Dr. Girija Kuttan, where she began her exploration into natural compounds with anti-cancer properties. Her graduate studies laid a strong foundation in experimental biology and immunomodulation. Eager to expand her research horizons globally, she pursued postdoctoral training at the Weizmann Institute of Science in Israel, and later at the prestigious MD Anderson Cancer Center, Texas, USA, where she transitioned into translational cancer research. This diverse academic journey spanning three countries has given Dr. Pradeep a unique global perspective, rigorous research training, and an innovative approach to solving complex oncological challenges.

Professional Experience:

Dr. Sunila Pradeep has more than 18 years of research experience in oncology and immunology. Her professional career began with a Postdoctoral Fellowship at the Weizmann Institute, where she explored molecular signaling in cancer progression. She then advanced to a key fellowship role at the MD Anderson Cancer Center, focusing on therapeutic resistance in ovarian cancer. Since joining the Medical College of Wisconsin as an Associate Professor, she has established herself as a leading researcher in ovarian tumor microenvironments, metastasis mechanisms, and extracellular vesicle biology. Her role extends beyond research—she is also a dedicated mentor to graduate students and postdocs, and contributes to several multidisciplinary cancer initiatives. Dr. Pradeep’s scientific rigor, grant success, and translational insights have made her a sought-after collaborator. Her efforts to bridge laboratory research with clinical application reflect her commitment to improving outcomes for women suffering from gynecologic cancers.

Awards and Honors:

Dr. Pradeep’s distinguished career has been marked by several prestigious awards. She received the Fr. Gabriel Award from the Amala Institute of Medical Sciences, Kerala, recognizing her excellence in immunology research. During her tenure at MD Anderson Cancer Center, she was honored with the Trainee Excellence Award, reflecting her high-impact work in cancer biology. Her promising contributions to ovarian cancer research earned her the Scholar-in-Training Award from the Marsha Rivkin Center Foundation for Ovarian Cancer Research—a significant achievement for emerging leaders in gynecologic oncology. These accolades underscore her strong scientific foundation, innovation, and leadership in translational oncology. Beyond individual awards, her prolific publication record and active engagement in scientific communities amplify her impact. Dr. Pradeep’s recognition across three continents emphasizes her global footprint and her consistent commitment to advancing women’s health through science.

Research Focus:

Dr. Sunila Pradeep’s research revolves around understanding tumor biology, metastasis, angiogenesis, immunomodulation, and drug resistance in gynecologic cancers, particularly ovarian and uterine cancers. She investigates the role of extracellular vesicles, tumor-derived signals, and the tumor microenvironment in driving cancer progression and therapy evasion. Her lab explores novel biomarkers and targets for overcoming VEGF resistance, improving chemotherapy response, and modulating the immune system to suppress tumor growth. Her translational work includes identifying new combination therapies (e.g., selinexor with eribulin) and examining gut microbiota’s role in estrogen signaling—connecting metabolic and hormonal networks with cancer biology. She is also involved in cutting-edge research on RNA-binding proteins, such as FXR1, and their roles in mRNA translation in cancer. With cross-disciplinary collaborations and NIH-supported studies, her focus bridges fundamental discovery with real-world clinical applications. Her ultimate goal: to make therapies more precise, personalized, and effective for women with cancer.

Publications Top Notes: 

  1. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine

  2. Protective effect of Piper longum fruit ethanolic extract on radiation-induced damages in mice

  3. Expression of VEGF and VEGF receptors in tumor angiogenesis and malignancies

  4. Protective effect of Thuja occidentalis against radiation-induced toxicity in mice

  5. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis

  6. Antimetastatic activity of Thuja occidentalis in a mouse model

  7. Inhibition of carcinogenesis by homeopathic drugs

  8. Effect of homeopathic medicines on transplanted tumors in mice

  9. Dynamized preparations in cell culture

  10. Phosphomimetic mutants of PEDF with enhanced antiangiogenic activity as anticancer agents

Conclusion:

Overall, Dr. Sunila Pradeep is highly qualified and a strong candidate for a Best Researcher Award in ovarian cancer research. Her prolific publication record, substantial citation impact, and focus on innovative cancer biology and treatment research provide a solid foundation for recognition. By highlighting her leadership contributions, translational impact, and broader scientific engagement, she can further strengthen her nomination. Her work clearly advances the field of ovarian cancer and serves as a model for impactful biomedical research, making her a deserving contender for such a prestigious award.

 

Doaa Esmaeil | Cancer treatment | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Doaa Esmaeil | Cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Doaa Esmaeil , Mansoura university , Egypt

Dr. Doaa Abd Elmoneim Mohamed Esmaeil is an Associate Professor of Oral Pathology at Mansoura University, Egypt. She is a dedicated researcher focused on oral diseases, particularly in understanding their pathogenesis, molecular biology, and carcinogenesis. With a strong background in oral pathology, she has contributed to numerous studies and publications that explore various aspects of oral health, including cancer research and therapeutic strategies. Dr. Esmaeil’s research includes innovative work on the effects of different agents and treatments in combating oral diseases. Her extensive academic contributions have established her as a prominent figure in the field of oral pathology, both in Egypt and internationally. She is committed to advancing the understanding of oral diseases, particularly those linked to cancer, and plays an active role in advancing the knowledge of oral health practices.

Publication Profile:

Orcid

Strengths for the Award:

  1. Academic Excellence: Dr. Doaa Esmaeil is an Associate Professor in the Oral Pathology Department at Mansoura University, Egypt, with a strong academic background and expertise in oral diseases, particularly oral carcinogenesis and molecular biology. Her contributions to the scientific community through both teaching and research have made her a significant figure in the field.

  2. Research Contributions: Dr. Esmaeil has made notable contributions to oral pathology through her innovative research on molecular mechanisms in oral diseases, focusing on cancer pathogenesis, therapeutic agents, and disease prevention. Her research projects, such as exploring the efficacy of phytomedicines against chemotherapy-induced toxicity, demonstrate her commitment to improving therapeutic outcomes.

  3. International Recognition: She has published several papers in high-impact journals such as the European Journal of Dentistry, Saudi Dental Journal, and the Egyptian Dental Journal, showcasing her widespread impact in the field of oral pathology.

  4. Ongoing Contributions to the Field: Dr. Esmaeil’s research is forward-thinking, addressing cutting-edge topics like stem cells in oral cancer therapy, the role of molecular markers in oral diseases, and enhancing chemotherapeutic efficacy against head and neck cancers.

Areas for Improvement:

  1. Citation Impact: While Dr. Esmaeil has been an active researcher with publications in reputed journals, her citation index of 3, while a good start, could benefit from increased visibility and collaborations with larger research networks to elevate her work’s recognition and citation in the broader academic community.

  2. Industry Collaborations: Although Dr. Esmaeil’s academic and research work is notable, there appears to be limited documented collaboration with industry projects or patents. Strengthening connections with industry could help translate her research into practical applications, potentially enhancing the impact of her work.

  3. Multidisciplinary Collaboration: While Dr. Esmaeil has collaborated with researchers within the field of oral pathology, expanding these collaborations into multidisciplinary domains could provide a more comprehensive approach to her research and open new avenues for funding and innovation.

Education:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil earned her Bachelor’s degree in Dental Medicine from Mansoura University, Egypt. She then pursued her Master’s and Ph.D. degrees in Oral Pathology, also from Mansoura University, where she developed a keen interest in the molecular mechanisms of oral diseases. Her academic journey has been enriched by her work on various research projects exploring oral carcinogenesis, molecular biology, and the development of therapeutic strategies for oral cancers. Dr. Esmaeil’s dedication to research and her extensive educational background have established her as an expert in oral pathology. She has participated in numerous international and national conferences, strengthening her expertise in both academic and clinical settings. Her education and commitment to continuous learning have shaped her approach to understanding and treating oral diseases, and she remains an influential educator and researcher at Mansoura University.

Experience:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil has over a decade of experience in teaching and researching in the field of oral pathology. As an Associate Professor in the Oral Pathology Department at Mansoura University, she has played a pivotal role in educating undergraduate and postgraduate students in both theoretical and practical aspects of oral pathology. Her experience extends to leading numerous research projects in oral diseases, with a special focus on oral cancer, its molecular mechanisms, and therapeutic approaches. Dr. Esmaeil’s work on tissue biomarkers, cancer stem cells, and chemotherapeutic agents has been recognized internationally. Additionally, her role as a reviewer for several scientific journals has solidified her standing as a respected authority in oral pathology. Her collaborative projects with other universities and institutions, both local and international, have further enhanced her research expertise. Dr. Esmaeil’s passion for education and research continues to shape the future of oral pathology.

Research Focus:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil’s research primarily focuses on the molecular pathogenesis of oral diseases, with a particular emphasis on oral cancer. Her work explores the complex mechanisms underlying carcinogenesis in the oral cavity, particularly focusing on the molecular markers, cell lines, and signaling pathways involved in cancer progression. Dr. Esmaeil is also interested in developing innovative therapeutic strategies for oral diseases, with research exploring the efficacy of various agents, including phytomedicines and synthetic compounds, against oral cancer and other related disorders. Her ongoing research examines the effectiveness of combining traditional treatments with new molecular-targeted therapies to improve patient outcomes. Additionally, she has investigated the role of cancer stem cells in therapy resistance and the development of new treatment modalities. Dr. Esmaeil’s research contributes to the broader understanding of oral diseases, aiming to improve both prevention and treatment options for conditions like oral squamous cell carcinoma.

Publication Top Notes:

  • The Impact of Silver Diamine Fluoride and Potassium Iodide Treatment on Microtensile Bonds Strength of Composite Restoration for Carious Dentin in Primary and Permanent Teeth and Its Potential Color Changes: An in Vitro Study 📄🦷

  • Antitumoral properties of the pomegranate peel and blueberry extracts against tongue carcinoma (in vitro study) 🍊🍇🦷

  • Oral squamous cell carcinoma Immunohistochemical Expression of PD L1 in Oral Epithelial Dysplasia 🦷🔬

  • Stem Cell Marker as A Factor for The Different Biological Behavior of Ameloblastoma and Odontogenic Keratocyst 🧬🦷

  • Diagnostic Value of Nuclear Receptor Subfamily 4 Group A Member 3 in Salivary Gland Carcinomas 🔬🦷

  • The controversial role of MDM2, MCM3 and Bcl-X in Ameloblastoma and Ameloblastic Carcinoma: An update 🧬🦷

  • Pomegranate molasses and red grape vinegar: can they alleviate dysplastic changes in chemically induced oral squamous cell carcinoma in hamsters? 🍑🍇🦷

  • Tumor stroma ratio as a parameter for prognosis and clinicopathological behavior of oral squamous cell carcinoma: A retrospective cohort study 📊🦷

  • Emerging therapeutic modality enhancing the efficiency of chemotherapeutic agents against head and neck squamous cell carcinoma cell lines 💊🦷

  • Angiogenesis and mast cells as predictive factors in behavior of Odontogenic cysts 🌱🦷

Conclusion:

Dr. Doaa Abd Elmoneim Mohamed Esmaeil is highly deserving of the Best Researcher Award. Her academic excellence, profound contributions to oral pathology, and commitment to advancing the understanding of oral diseases and cancer pathogenesis make her a strong candidate. By focusing on broadening her citation impact and enhancing her industry collaborations, Dr. Esmaeil has the potential to elevate her career to even greater heights. Her continued research and dedication to the scientific community position her as an influential researcher in the field of oral pathology, contributing not only to academia but also to real-world applications in oral healthcare.

Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Ana Figueiras , Faculty of Pharmacy/University of Coimbra , Portugal

Ana Rita Ramalho Figueiras is an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, Portugal, and a researcher at REQUIMTE/LAQV, focusing on Pharmaceutical Technology. She earned her PhD in Pharmaceutics from the University of Coimbra in 2009, specializing in drug delivery systems, particularly for cancer treatments. Throughout her career, Ana has worked on advancing the development of block copolymers and micellar systems for targeted drug delivery. With a strong academic background and international exposure, she has contributed significantly to the fields of pharmaceutics, drug formulation, and pharmaceutical sciences. Ana’s work has been recognized through various publications in top journals, and she is deeply involved in mentoring post-doctoral researchers. Her expertise and leadership in pharmaceutical research continue to influence the development of innovative therapies in the pharmaceutical field.

Publication Profile: 

Orcid

Strengths for the Award:

Ana Rita Ramalho Figueiras is a highly accomplished researcher in pharmaceutical sciences, with extensive contributions to drug delivery systems, particularly focusing on micellar systems and polymeric micelles for cancer therapy. Her interdisciplinary work bridges pharmaceutics, chemistry, and biomedicine, showcasing her ability to innovate within drug delivery mechanisms for complex diseases. As an Assistant Professor at the University of Coimbra and an integrated member of the REQUIMTE/LAQV research group, she brings a wealth of academic and research leadership to her field.

Her innovative contributions have been recognized with various academic awards, including distinctions for oral communications and publications. Additionally, she has made substantial contributions to numerous collaborative research projects, focusing on the development of novel therapeutic strategies and drug delivery systems that target poorly soluble drugs, cancer therapies, and chronic diseases like Alzheimer’s.

Areas for Improvement:

While Figueiras is a leading figure in the scientific community, expanding her outreach to a broader range of international research collaborations could further amplify her impact. Although her work on drug delivery systems has significant potential for clinical applications, there could be further focus on translating her findings from bench to bedside by collaborating with clinical researchers for clinical trials and regulatory studies. A stronger emphasis on commercialization of her research could also be beneficial for broader societal impact.

Education:

Ana Rita Ramalho Figueiras pursued her academic journey in the field of Pharmaceutical Sciences, beginning at the University of Coimbra in Portugal. She graduated with a degree in Pharmaceutical Sciences in 2002, followed by a PhD in Pharmaceutics at the same university in 2009. Her doctoral research was focused on enhancing drug solubility and permeability, with a specific focus on cyclodextrins and mucoadhesive polymers for buccal drug delivery. During her PhD, she gained international exposure by collaborating with the University of Santiago de Compostela, Spain, and the University of Innsbruck, Austria. She is also registered as a member of the Ordem dos Farmacêuticos in Portugal since 2003. Ana’s educational foundation, combined with her interdisciplinary collaborations, has provided her with a robust understanding of pharmaceutical sciences and technologies, forming the cornerstone of her impactful career in academia and research.

Experience:

Ana Rita Ramalho Figueiras has been an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, since September 2014, where she is an integrated Ph.D. member in the Pharmaceutical Technology group of REQUIMTE/LAQV. Prior to this, she was an Invited Assistant Professor from 2013 to 2014, working closely with the Center of Neuroscience and Cell Biology (CNC/UC) and contributing as a collaborator in the Health Sciences Research Centre (CICS/UBI). Her academic roles involve teaching, mentoring students and postdoctoral fellows, and leading research projects on advanced drug delivery systems. She has also been involved in supervising several postdoctoral researchers, focusing on developing and characterizing polymeric micellar systems and controlled delivery systems for drugs like pilocarpine. Throughout her career, Ana has participated in various scientific projects, bringing valuable insights into the design of innovative drug delivery platforms with applications in cancer therapy and other medical conditions.

Awards and Honors:

Ana Rita Ramalho Figueiras has received several accolades for her research excellence and contributions to the field of Pharmaceutical Sciences. In 2004, she was awarded a prestigious PhD fellowship by Fundação para a Ciência e Tecnologia (FCT), which enabled her to pursue her doctoral studies. In 2011, she received the Best Short Communication Award at the VI Annual CICS Symposium for her work on new therapeutic strategies for siRNA delivery. In 2012, she was honored with the Best Oral Communication Award for her research on Poloxamine-α-cyclodextrin supramolecular gels promoting osteogenic differentiation of mesenchymal stem cells. These awards underscore her commitment to scientific advancement, as she continues to lead innovative research in drug delivery systems, nanomedicine, and cancer therapy. Ana’s dedication to advancing pharmaceutics has also led her to mentor future generations of researchers, further solidifying her reputation as a leading academic in her field.

Research Focus:

Ana Rita Ramalho Figueiras focuses her research on developing advanced drug delivery systems, specifically in the context of cancer therapies. Her primary research interest lies in utilizing block copolymers and micellar systems for targeted and controlled drug release. This includes the formulation of poorly water-soluble drugs, improving their bioavailability, and creating novel pharmaceutical formulations for effective treatment. Ana is particularly interested in the development of polymeric micelles for the delivery of therapeutic agents, including drugs and genes, to treat various diseases, with a strong emphasis on oncology. Additionally, her research investigates the use of mucoadhesive polymers for drug delivery to mucosal surfaces. With a commitment to improving drug efficacy and reducing side effects, her work aims to enhance patient outcomes through innovative drug formulations. Ana is also involved in several projects that explore natural compounds and their potential for pharmaceutical applications, further contributing to advancements in the drug delivery and pharmaceutical fields.

Publications Top Notes:

  1. “Unraveling Rosmarinic Acid Anticancer Mechanisms in Oral Cancer Malignant Transformation” 🎗️🦷
  2. “Regulation and Safety of Cosmetics: Pre- and Post-Market Considerations for Adverse Events and Environmental Impacts” 💄⚖️
  3. “The Many Faces of Cyclodextrins within Self-Assembling Polymer Nanovehicles: From Inclusion Complexes to Valuable Structural and Functional Elements” 🔬🧪
  4. “Development and Characterization of Curcumin-Loaded TPGS/F127/P123 Polymeric Micelles as a Potential Therapy for Colorectal Cancer” 🍂⚕️
  5. “Pulmonary Delivery of Bacterial Lysates Mediated by Locust Bean Gum Microparticles” 🌬️🦠
  6. “Non-Toxic Mucoadhesive Locust Bean Gum Microparticles for Delivery of Bacterial Lysates to Prevent Respiratory Diseases” 🌱🫁
  7. “Polymersomes as the Next Attractive Generation of Drug Delivery Systems: Definition, Synthesis and Applications” 🧫💊
  8. “Nanotheranostics: The Afterglow for Cancer Immunotherapy” 💡💉
  9. “Acanthus Mollis Formulations for Transdermal Delivery: From Hydrogels to Emulsions” 🌿💧
  10. “A Review of the Application of Ganoderma Lucidum (Curtis) P. Karst. in Nanotechnology for the Treatment of Cancer” 🍄💻

Conclusion:

Ana Figueiras’ expertise in pharmaceutical technology, particularly in the development of polymeric micelles for drug delivery, marks her as an outstanding candidate for the Best Researcher Award. She is an exemplary figure in the realm of pharmaceutics with a strong research focus on improving drug therapies for cancer and other severe diseases. Her work continues to advance drug delivery systems, paving the way for future medical breakthroughs. Figueiras demonstrates a strong foundation in academic excellence, research innovation, and collaboration, positioning her as a leader in her field.

Vaibhav Rajoriya | Cancer Cell Biology | Cell Biology Research Award

Published on by Cell Biologist

Mr. Vaibhav Rajoriya | Cancer Cell Biology | Cell Biology Research Award

Mr. Vaibhav Rajoriya , Oriental University, Indore , India

Vaibhav Rajoriya is a dedicated and accomplished researcher and pharmacist based in Sagar, Madhya Pradesh, India. With a strong academic background, he has earned his B.Pharm and M.Pharm from renowned institutions. He is a registered pharmacist with the MP State Pharmacy Council and holds memberships in various professional organizations, including the Association of Pharmacy Professionals. As a passionate researcher, Vaibhav has contributed to numerous studies, particularly focusing on nanomedicine, drug delivery systems, and cancer therapies. He has received prestigious fellowships such as ICMR-SRF and CSIR-SRF, contributing significantly to the field of pharmaceutical sciences. Currently pursuing a Ph.D., Vaibhav’s work continues to push boundaries in pharmaceutical research and development. His drive for excellence is further reflected in his active participation in various national and international conferences and research collaborations.

Publication Profile:

Orcid

Strengths for the Award:

  1. Diverse and Strong Research Background:
    • Vaibhav Rajoriya has a robust academic and research profile, with an established history of contributions to pharmaceutical sciences, particularly in the areas of drug delivery, nanotechnology, and cancer therapies.
    • He has authored multiple publications in high-impact journals, such as International Journal of Pharmaceutics and Current Nanomedicine, which demonstrate his expertise in nanomedicine, drug delivery systems, and the pharmaceutical applications of lipid nanoparticles and nanogels.
    • His focus on cutting-edge research areas, such as lung cancer targeting with folate-conjugated nanoparticles and novel drug delivery systems using solid lipid nanoparticles, shows a clear alignment with important biological research themes, including targeted therapy and cellular uptake.
  2. Research Achievements and Awards:
    • He has received prestigious recognitions, such as the MPCST Young Scientist Award and Best Poster Awards from institutions like AIIMS, Rishikesh, and IIT-BHU. These accolades reflect the high quality and relevance of his work in the biomedical field.
    • His successful completion of ICMR-SRF and CSIR-SRF fellowships exemplifies his ability to lead significant research projects. Moreover, he has actively contributed to a variety of projects in pharmaceutical science, indicating a deep understanding of the complexities of drug formulations, targeting mechanisms, and therapeutic applications.
  3. Ph.D. Candidacy and Future Potential:
    • Vaibhav Rajoriya is currently pursuing a Ph.D. at Oriental University, Indore, demonstrating his commitment to further advancing his research capabilities and contributing to cutting-edge research in cell biology and drug development.
    • His experience and involvement in multi-disciplinary projects, along with his fellowship positions, position him to be a strong contender for advanced research awards, including in the field of cell biology.
  4. Collaborative and Multi-dimensional Approach:
    • His involvement in collaborative research is evident through co-authorship in studies that blend different scientific approaches (nanotechnology, pharmacology, and medicinal chemistry). Such collaborations show his adaptability and the potential for cross-pollination of ideas between different scientific domains, an important characteristic in cell biology research.

Areas for Improvement:

  1. Focus on Cell Biology-Specific Research:
    • While Vaibhav’s work in nanomedicine and drug delivery systems has implications for cell biology, the research could benefit from a more explicit focus on cell biology topics such as cell signaling, cell-matrix interactions, or cell morphology, particularly at the molecular level.
    • His research could further explore in vivo and ex vivo models to study the cellular response in the context of drug delivery, providing a direct link to cellular behavior and biological mechanisms.
  2. Publication Expansion in Cell Biology Journals:
    • While his work is widely published in pharmaceutically inclined journals, increasing the number of publications directly in cell biology and molecular biology journals would provide a stronger case for this specific award. It could enhance his visibility and establish his position as a leading researcher in this field.
  3. Broader Approach to Targeted Drug Delivery in Cell Biology:
    • The research could be expanded by investigating multi-targeted delivery systems that engage specific cell types or signaling pathways, thereby providing deeper insights into cellular responses to treatment, as well as optimizing efficacy in various disease models, particularly cancer and genetic disorders.

Education:

Vaibhav Rajoriya’s educational journey is marked by a focus on pharmaceutical sciences and research. He completed his Standard X and XII from Jain Higher Secondary School, Sagar, achieving 69% and 68%, respectively. Vaibhav pursued his B.Pharm from Sagar Institute of Pharmaceutical Sciences, securing 70.4% and completed his M.Pharm at Adina Institute of Pharmaceutical Sciences with an impressive 79.9%. In addition to his pharmaceutical qualifications, Vaibhav obtained a PGDCA (Post Graduate Diploma in Computer Applications) from Agrabhan Institute of Excellence. His pursuit of knowledge led him to enroll in a Ph.D. program at Oriental University, Indore, in 2022, to further his expertise in pharmaceutical research. Throughout his academic career, he has demonstrated a strong foundation in various fields, including drug delivery systems and nanotechnology, which continues to shape his innovative research.

Experience”

Vaibhav Rajoriya has extensive experience in the field of pharmaceutical sciences, with a career that spans various research positions and projects. He was a Junior Research Fellow (JRF) in the DST-SERB-sponsored project from May 2016 to June 2018, followed by a Project Fellow position in the MPCST-sponsored research project from 2014 to 2016. These roles allowed him to gain hands-on experience in scientific research, contributing to the advancement of drug delivery systems and nanomedicine. Vaibhav has been awarded prestigious fellowships, including the ICMR-SRF (2018–2021), which further honed his skills in biomedical research. He has worked on numerous research topics, particularly focused on targeted drug delivery for cancer and other diseases, which resulted in multiple publications in high-impact journals. Vaibhav’s expertise spans the development of nanoparticle-based drug delivery systems, nano-lipid carriers, and the formulation of pharmaceutical compounds with specific targeting properties.

Awards and Honors:

Vaibhav Rajoriya’s exceptional contributions to pharmaceutical sciences have earned him several prestigious awards and honors. Notably, he was the recipient of the MPCST Young Scientist Award in 2018, recognizing his contributions to innovative research in nanomedicine. He has also earned accolades for his research presentations, including the Best Poster Award at AIIMS, Rishikesh, in 2018, for his work on folate-conjugated solid lipid nanoparticles for cancer treatment. In addition, Vaibhav won the Outstanding Poster Presentation Award in the Life Sciences category at the 1st National Biomedical Research Competition in 2018. His work at the 3rd SPIRIT 2019 conference earned him the 3rd position in the poster presentation, further highlighting his research prowess. These accolades reflect Vaibhav’s deep commitment to advancing pharmaceutical research, particularly in targeted drug delivery systems and cancer therapies, as well as his ability to effectively communicate his findings on national and international platforms.

Research Focus:

Vaibhav Rajoriya’s research focus lies primarily in the development of novel drug delivery systems, particularly for cancer treatment and other chronic diseases. His work explores the use of nanomedicine, including the formulation of solid lipid nanoparticles, nano-lipid carriers, and targeted drug delivery systems. Vaibhav’s research aims to enhance the bioavailability and therapeutic efficacy of drugs, particularly in targeted therapies for lung carcinoma and other cancers. He is particularly interested in the design and optimization of nanoparticles conjugated with targeting moieties such as folate and mannosylation to improve cellular uptake and reduce side effects. Through his research, Vaibhav has contributed to the advancement of nanocarriers for targeted drug delivery, studying their physicochemical properties, drug release profiles, cytotoxicity, and in vivo behavior. His focus is on using cutting-edge nanotechnology to create more effective and precise drug therapies for patients, particularly in oncology and infectious diseases.

Publications Top Notes:

  1. “Lactosaminated-Nsuccinyl Chitosan Nanoparticle for Hepatocyte-Targeted Delivery of Acyclovir” 🧬
  2. “Glycyrrhizin Conjugated Chitosan Nanoparticles for Hepatocyte-Targeted Delivery of Lamivudine” 💊
  3. “Mannosylated Solid Lipid Nanoparticles for Lung Targeted Delivery of Paclitaxel” 🌱
  4. “Folate-Conjugated Albumin Nanoparticles for Rheumatoid Arthritis-Targeted Delivery of Etoricoxib” 🦴
  5. “Development and Validation of RP-HPLC Method for Theophylline and Motelukast Estimation” 🔬
  6. “Evaluation of Ethanolic Extract of Zizyphus Xylopyrus on Wound Healing Activity” 🩹
  7. “Formulation Development and Evaluation of Fast Dissolving Tablet of Ramipril” 💊
  8. “UV-Spectrophotometric and Stability-Indicating RP-HPLC Method for Amlodipine and Indapamide” 📊
  9. “Folate-Conjugated Nano-Lipid Construct of Paclitaxel for Site-Specific Lung Squamous Carcinoma Targeting” 🫁
  10. “Nanostructured Lipid Carriers for Lung Cancer Targeting” 💥

Conclusion:

Vaibhav Rajoriya is a highly capable and promising researcher with strong achievements in pharmaceutical sciences, nanomedicine, and drug delivery systems. His research in the area of targeted drug delivery to specific cell types (e.g., cancer cells) already touches on key aspects of cell biology. His extensive background in various fellowships and awards underscores his dedication and success in research.